Nuvalent, Inc. develops cancer therapies and has two lead product candidates: NVL-520 and NVL-655. Both are brain-penetrant inhibitors, with NVL-520 targeting ROS1 fusions and NVL-655 targeting ALK. The company was founded in 2017 and is based in Cambridge, Massachusetts.